公开(公告)号：US4668629A

公开(公告)日：1987-05-26

申请号：US599201

申请日：1984-04-09

申请人： Henry S. Kaplan ,  Lennart Olsson

发明人： Henry S. Kaplan ,  Lennart Olsson

IPC分类号： A61K39/395 ,  C07K16/00 ,  C12N5/16 ,  C12N5/00 ,  C12N15/00

CPC分类号： C12N5/163 ,  A61K39/395 ,  C07K16/00

摘要： Human monoclonal antibody compositions, human-human monoclonal hybridoma cells, human myeloma cells, human antibody genes and their uses. Human myeloma cells are developed for fusing with immunized lymphoid cells to provide stable human-human hybridoma strains producing complete monoclonal antibodies for a predefined antigen. From a myeloma cell line, rapidly growing 8-azaguanine resistant HAT sensitive cells are selected. The selected myeloma cells are crossed with immunized lymphoid cells and the resulting cell mixture grown under controlled selective conditions. After expansion of the desired hybridoma cells, the monoclonal antibodies may be harvested. The hybridomas serve as a source for messenger RNA for light and heavy chains which may be used for production of light and heavy chain immunoglobulin proteins through hybrid DNA techniques.

摘要翻译： 人单克隆抗体组合物，人 - 人单克隆杂交瘤细胞，人骨髓瘤细胞，人抗体基因及其用途。 开发人类骨髓瘤细胞用于与免疫淋巴细胞融合以提供稳定的人 - 人杂交瘤菌株，其产生预定抗原的完整单克隆抗体。 从骨髓瘤细胞系中，选择快速生长的8-氮鸟嘌呤抗性HAT敏感细胞。 将所选择的骨髓瘤细胞与免疫淋巴细胞杂交，并将所得细胞混合物在对照选择条件下生长。 在所需杂交瘤细胞扩增后，可以收获单克隆抗体。 杂交瘤作为轻链和重链的信使RNA的来源，可用于通过杂交DNA技术生产轻链和重链免疫球蛋白。

公开(公告)号：US5426046A

公开(公告)日：1995-06-20

申请号：US112048

申请日：1993-08-25

申请人： Henry S. Kaplan ,  Abraham I. Braude ,  Nelson N. H. Teng

发明人： Henry S. Kaplan ,  Abraham I. Braude ,  Nelson N. H. Teng

IPC分类号： A61K38/00 ,  C07K16/12 ,  C12N5/12

CPC分类号： C07K16/1203 ,  A61K38/00

摘要： A human monoclonal antibody, C5, specific for lipid A of the endotoxin core of Gram-negative bacteria and the hybridoma cell line which produces the antibody. The monoclonal antibody is produced by the fusion of lipid A sensitized lymphocytes and an appropriate fusion partner.

摘要翻译： 对革兰氏阴性细菌的内毒素核心的脂质A和产生抗体的杂交瘤细胞系特异性的人单克隆抗体C5。 单克隆抗体通过融合脂质A致敏淋巴细胞和合适的融合配偶体产生。

公开(公告)号：US4574116A

公开(公告)日：1986-03-04

申请号：US457795

申请日：1983-01-13

申请人： Henry S. Kaplan ,  Nelson N. H. Teng ,  Kit S. Lam ,  Francisco Calvo-Riera

发明人： Henry S. Kaplan ,  Nelson N. H. Teng ,  Kit S. Lam ,  Francisco Calvo-Riera

IPC分类号： C12N5/26 ,  C12P21/08 ,  C12P21/00 ,  C12N5/00 ,  C12N13/00 ,  C12N15/00

CPC分类号： C12N5/166 ,  Y10S435/948

摘要： Methods are provided for producing fusion partners which involve employing an immortalized human myeloma cell line sensitive to HAT and having an additional dominant selectable resistance marker and fusing the doubly marked human myeloma cells with a stable immortalized rodent myeloma cell line, desirably previously subjected to substantial chromosome damage, and isolating cells having a substantially complete chromosomal complement of the rodent cell and at least about one chromosome of the human cell having a gene expressing said resistance, thereby being resistant to a selective agent. The resulting heteromyeloma may be fused with high efficiency with human lymphocytes to produce monoclonal antibodies.The cell lines designated as A6 and 36 were deposited at the A.T.C.C. on Jan. 11, 1983 and given accession numbers CRL8192 and CRL8193, respectively.

摘要翻译： 提供了用于产生融合伴侣的方法，其涉及使用对HAT敏感的永生化人骨髓瘤细胞系并具有另外的显性可选择抗性标记，并将双重标记的人骨髓瘤细胞与稳定的永生化啮齿动物骨髓瘤细胞系融合，期望预先经受实质性染色体 损伤和分离具有基本上完整的啮齿动物细胞染色体补体的细胞和具有表达所述抗性的基因的人细胞的至少约一个染色体，从而对选择剂具有抗性。 所得到的异源骨髓瘤可以与人淋巴细胞高效融合以产生单克隆抗体。 指定为A6和36的细胞系保藏在A.T.C.C. 1983年1月11日，分别登录号为CRL8192和CRL8193。